Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
02:36:32 EDT Sat 28 Jun 2025
Enter Symbol
or Name
USA
CA



Q:AVXL - ANAVEX LIFE SCIENCES CORPORATION - https://www.anavex.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
AVXL - Q0.59.25·10.420.19.48-0.09-0.92,817.126,4795,4969.66  9.78  9.2814.4405  4.0019:53:28May 1415 min RT 2¢

Recent Trades - Last 10 of 5496
Time ETExPriceChangeVolume
19:53:28Q9.307-0.263100
19:49:07Q9.35-0.221
19:02:24Q9.30-0.27320
19:01:29Q9.3164-0.253690
17:38:43Q9.25-0.3210
16:34:44Q9.48-0.0982
16:29:15Q9.4803-0.08973,560
16:29:15Q9.4797-0.0903148,078
16:27:52Q9.48-0.093,281
16:27:51Q9.48-0.097,495

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-05-14 07:30U:AVXLNews ReleaseAnavex Life Sciences to Participate at Upcoming Healthcare Conferences
2025-05-13 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update
2025-05-06 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
2025-05-01 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX(TM)3-71 for the Treatment of Schizophrenia
2025-04-30 07:30U:AVXLNews ReleaseAnavex Life Sciences to Participate in The Citizens Life Sciences Conference
2025-04-23 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
2025-04-21 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
2025-04-05 11:30U:AVXLNews ReleaseAnavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease
2025-03-31 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
2025-02-24 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
2025-02-12 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
2025-02-05 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
2025-01-27 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX(TM)2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
2025-01-15 07:30U:AVXLNews ReleaseAnavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease
2025-01-13 07:30U:AVXLNews ReleaseNew Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease Patients
2025-01-06 07:30U:AVXLNews ReleaseAnavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-23 07:30U:AVXLNews ReleaseAnavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
2024-12-23 07:00U:AVXLNews ReleaseBlarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's Disease
2024-12-16 07:30U:AVXLNews ReleaseAnavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
2024-12-09 07:30U:AVXLNews ReleaseAnavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare Conference